Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-STING Trial: Universal Donor NK Cells + Chemo-Immunotherapy in Relapsed/Refractory Neuroblastoma
NCT04211675Phase 2Active, not recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Natural Killer Cells in neuroblastoma and ganglioneuroblastoma (GNB), sponsored by Nationwide Children's Hospital. Primary endpoints: Number of participants with treatment-related adverse events and toxicities at 12 months, Response to NK Cell treatment as determine by CT/MRI imaging at 24 months and 2 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
Natural Killer Cells
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT04211675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211675.